Geometrical Influences on Atherosclerosis and Blood Flow
Launched by BANGLADESH UNIVERSITY OF ENGINEERING AND TECHNOLOGY · May 25, 2025
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Geometrical Influences on Atherosclerosis and Blood Flow," is looking at how advanced imaging and computer analysis can help identify dangerous plaque build-up in the coronary arteries, which can lead to serious heart problems like heart attacks. The study is combining a type of non-invasive imaging called Coronary Computed Tomography (CCT) with a technique that simulates blood flow (Computational Fluid Dynamics or CFD) to better understand the characteristics of these plaques and how they affect blood flow. The goal is to find high-risk plaques earlier and provide better information to doctors for decision-making.
To participate in the trial, adults aged 40 to 70 years who have symptoms of coronary artery disease, such as chest pain or shortness of breath, or have multiple risk factors like high blood pressure or diabetes, may be eligible. Participants will undergo non-invasive imaging and analysis to assess their coronary health. However, individuals with severe kidney problems, a history of allergic reactions to certain contrast dyes, or who are pregnant or breastfeeding cannot join. This trial is currently recruiting participants and aims to improve early detection of heart risks, ultimately helping to prevent serious heart events.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 40-70 years.
- • Presenting with symptoms of CAD (e.g., chest pain, shortness of breath) or having multiple risk factors (e.g., hypertension, diabetes, smoking).
- • Able to provide informed consent.
- Exclusion Criteria:
- • Severe renal impairment (due to contrast media risk).
- • Previous allergic reaction to iodinated contrast media.
- • Pregnant or lactating women.
About Bangladesh University Of Engineering And Technology
The Bangladesh University of Engineering and Technology (BUET) is a premier institution dedicated to advancing engineering and technology in Bangladesh through research and innovation. As a clinical trial sponsor, BUET leverages its robust academic resources and interdisciplinary expertise to conduct high-quality research that addresses critical health challenges. The university is committed to ethical standards and regulatory compliance, ensuring that all trials contribute valuable insights to the scientific community while prioritizing participant safety and well-being. Through collaboration with healthcare professionals and researchers, BUET aims to foster advancements in medical science and improve healthcare outcomes in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dhaka, , Bangladesh
Patients applied
Trial Officials
Muhammad Tarik Arafat, PhD
Principal Investigator
Department of Biomedical Engineering, Bangladesh University of Engineering and Technology (BUET), Dhaka - 1205
Dr. M G Azam, MBBS, MD, FSCAI
Principal Investigator
NICVD, Dhaka
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported